Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account
Nestle in talks with EQT, ADIA for $10bn skin health deal
Published by
Reuters

1m read

16 May 7.25am

Hargreaves Lansdown is not responsible for this article's content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest. Article originally published by Reuters.

Nestle SA has entered exclusive negotiations to sell its skin health business to a consortium led by private equity firm EQT Partners and ADIA in a deal worth 10.2 billion Swiss francs ($10.12 billion), it said on Thursday.

The proposed transaction with EQT and a unit of the Abu Dhabi Investment Authority (ADIA) was expected to close in the second half of 2019 pending regulatory approval.

Nestle will provide an update on how it will use the proceeds and its future capital structure at that time, the world's biggest food group said in a statement.

Reuters and the Financial Times had reported on Wednesday that EQT was putting the finishing touches on the deal.

EQT and ADIA had faced competition from rival buyout funds and some industry players including a consortium of Advent and Cinven as well as U.S. private equity firm KKR & Co Inc and European fund PAI Partners, sources had said.

Nestle's skin health unit, which sells Cetaphil, was formed in 2014. The unit was put up for sale last September as Nestle tries to ditch underperforming businesses in an effort to fend off criticism from an activist investor.

Nestle Sa

Sell: 98.99 | Buy: 99.00 negative 0.32 (-0.32%)
Graph

Prices delayed by at least 15 minutes.

Nestle Skin Health had net sales of 2.8 billion Swiss francs in 2018. Based in the Swiss city of Lausanne, it employs more than 5,000 people across 40 countries.

($1 = 1.0079 Swiss francs)

Copyright (2019) Thomson Reuters. This article was from Reuters and was legally licensed through the NewsCred publisher network. Please direct all licensing questions to legal@newscred.com.

Free Newsroom email alerts

The headlines that matter to investors direct to your inbox

Register for daily/weekly email alerts with news from The Financial Times, Forbes, Reuters, The Economist and more.

Loading...
Share via emailShare on FacebookShare on TwitterShare on Linkedin

Article originally published by Reuters. Hargreaves Lansdown is not responsible for its content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.

Other stories

HL features

Latest tweet
Share via email Share on Facebook Share on Twitter Share on Linkedin